Genetic variability of matrix metalloproteinase genes in cardiovascular disease

Current Topics in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1206-1213

  Papageorgiou, Nikolaos ^a   Tousoulis, Dimitris ^a   Hatzis, George ^a   Briasoulis, Alexandros ^a   Androulakis, Emmanuel ^a   Giolis, Anastasios ^a   Siasos, Gerasimos ^a   Latsios, George ^a   Vogiatzi, Georgia ^a   Tentolouris, Costas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Coronary artery disease; Gene polymorphisms; Matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 26; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ACUTE CORONARY SYNDROME; ALLELE; ARTICLE; ASIAN; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CONCENTRATION (PARAMETERS); CORONARY ARTERY ATHEROSCLEROSIS; DEGRADATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; GENETIC VARIABILITY; HEART INFARCTION; HISPANIC; HUMAN; PROTEIN EXPRESSION; RACE;

EID: 84861120114     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611208011206     Document Type: Article

References (101)

1. Kulach, A.; Dabek, J.; Glogowska-Ligus, J.; Garczorz, W.; Gasior, Z. Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes. Pharmacol. Rep., 2010, 62, 1108-1116.
2. Koh, Y.S.; Chang, K.; Kim, P.J.; Seung, K.B.; Baek, S.H.; Shin, W.S.; Lim, S.H.; Kim, J.H.; Choi, K.B. A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. Int. J. Cardiol., 2008, 127, 430-432.
3. Wang, J.; Xu, D.; Wu, X.; Zhou, C.; Wang, H.; Guo, Y.; Cao, K. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart, 2011, 97, 1542-1546.
4. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
5. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003, 92, 827-839.
6. Galis, Z.S.; Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90, 251-262.
7. Newby, A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev., 2005, 85, 1-31.
8. Newby, A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res., 2006, 69, 614-624.
9. Nagase, H.; Visse, R.; Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res., 2006, 69, 562-73.
10. Somerville, R.P.; Oblander, S.A.; Apte, S.S. Matrix metalloproteinases: old dogs with new tricks. Genome Biol., 2003, 4, 216.
11. Baker, A.H.; Edwards, D.R.; Murphy, G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci., 2002, 115, 3719-27.
12. Choudhary, S.; Higgins, C.L.; Chen, I.Y.; Reardon, M.; Lawrie, G.; Vick, G.W. 3rd.; Karmonik, C.; Via, D.P.; Morrisett, J.D. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2351-2358.
13. Sukhova, G.K.; Schonbeck, U.; Rabkin, E.; Schoen, F.J.; Poole, A.R.; Billinghurst, R.C.; Libby, P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation, 1999, 99, 2503-2509.
14. Sluijter, J.P.; Pulskens, W.P.; Schoneveld, A.H.; Velema, E.; Strijder, C.F.; Moll, F.; de Vries, J.P.; Verheijen, J.; Hanemaaijer, R.; de Kleijn, D.P.; Pasterkamp, G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke, 2006, 37, 235-239.
15. Newby, A.C. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc. Med., 2007, 17, 253-258.
16. Death, A.K.; Fisher, E.J.; McGrath, K.C.; Yue, D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis, 2003, 168, 263-269.
17. Hanemaaijer, R.; Koolwijk, P.; le Clercq, L.; de Vree, W.J.; van Hinsbergh, V.W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem. J., 1993, 296 (Pt 3), 803-809.
18. Herman, M.P.; Sukhova, G.K.; Libby, P.; Gerdes, N.; Tang, N.; Horton, D.B.; Kilbride, M.; Breitbart, R.E.; Chun, M.; Schönbeck, U. Expression of neutrophil collagenase (matrix metalloproteinase- 8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation, 2001, 104, 1899-1904.
19. Mach, F.; Schönbeck, U.; Fabunmi, R.P.; Murphy, C.; Atkinson, E.; Bonnefoy, J.Y.; Graber, P.; Libby, P. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40Ldependent mechanism: implications for tubule formation. Am. J. Pathol., 1999, 154, 229-238.
20. Schönbeck, U.; Mach, F.; Sukhova, G.K.; Atkinson, E.; Levesque, E.; Herman, M.; Graber, P.; Basset, P.; Libby, P. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med., 1999, 189, 843-853.
21. Lee, E.; Grodzinsky, A.J.; Libby, P.; Clinton, S.K.; Lark, M.W.; Lee, R.T. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 2284-2289.
22. Sasaguri, T.; Arima, N.; Tanimoto, A.; Shimajiri, S.; Hamada, T.; Sasaguri, Y. A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis, 1998, 138, 247-253.
23. Schönbeck, U.; Mach, F.; Sukhova, G.K.; Murphy, C.; Bonnefoy, J.Y.; Fabunmi, R.P.; Libby, P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res., 1997, 81, 448-454.
24. Fabunmi, R.P.; Baker, A.H.; Murray, E.J.; Booth, R.F.; Newby, A.C. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases- 1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem. J., 1996, 315 (Pt 1), 335-342.
25. Fabunmi, R.P.; Sukhova, G.K.; Sugiyama, S.; Libby, P. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ. Res., 1998, 83, 270-278.
26. Rajavashisth, T.B.; Xu, X.P.; Jovinge, S.; Meisel, S.; Xu, X.O.; Chai, N.N.; Fishbein, M.C.; Kaul, S.; Cercek, B.; Sharifi, B.; Shah, P.K. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation, 1999, 99, 3103-3109.
27. Shipley, J.M.; Wesselschmidt, R.L.; Kobayashi, D.K.; Ley, T.J.; Shapiro, S.D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. U S A, 1996, 93, 3942-3946.
28. Hojo, Y.; Ikeda, U.; Takahashi, M.; Sakata, Y.; Takizawa, T.; Okada, K.; Saito, T.; Shimada, K. Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J. Mol. Cell. Cardiol., 2000, 32, 1459-1468.
29. Galis, Z.S.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94, 2493-2503.
30. Ross, R. Atherosclerosis is an inflammatory disease. Am. Heart J., 1999, 138, S419-420.
31. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-126.
32. Galis, Z.S.; Muszynski, M.; Sukhova, G.K.; Simon-Morrissey, E.; Unemori, E.N.; Lark, M.W.; Amento, E.; Libby, P. Cytokinestimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res., 1994, 75, 181-189.
33. Pauly, R.R.; Passaniti, A.; Bilato, C.; Monticone, R.; Cheng, L.; Papadopoulos, N.; Gluzband, Y.A.; Smith, L.; Weinstein, C.; Lakatta, E.G.; Crow, M.T. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ. Res., 1994, 75, 41-54.
34. Southgate, K.M.; Davies, M.; Booth, R.F.; Newby, A.C. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem. J., 1992, 288 (Pt 1), 93-99.
35. Yanagi, H.; Sasaguri, Y.; Sugama, K.; Morimatsu, M.; Nagase, H. Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis, 1991, 91, 207-216.
36. Southgate, K.M.; Fisher, M.; Banning, A.P.; Thurston, V.J.; Baker, A.H.; Fabunmi, R.P.; Groves, P.H.; Davies, M.; Newby, A.C. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ. Res., 1996, 79, 1177-1187.
37. Jeziorska, M.; Woolley, D.E. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J. Pathol., 1999, 188, 189-96.
38. George, S.J.; Zaltsman, A.B.; Newby, A.C. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc. Res., 1997, 33, 447-59.
39. Bendeck, M.P.; Zempo, N.; Clowes, A.W.; Galardy, R.E.; Reidy, M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res., 1994, 75, 539-45.
40. Chesler, N.C.; Ku, D.N.; Galis, Z.S. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am. J. Physiol., 1999, 277, H2002-2009.
41. Inoue, N.; Takeshita, S.; Gao, D.; Ishida, T.; Kawashima, S.; Akita, H.; Tawa, R.; Sakurai, H.; Yokoyama, M. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis, 2001, 155, 45-52.
42. Pasterkamp, G.; Schoneveldm, A.H.; Hijnen, D.J.; de Kleijn, D.P.; Teepen, H.; van der Wal, A.C.; Borst, C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis, 2000, 150, 245-253.
43. Hojo, Y.; Ikeda, U.; Ueno, S.; Arakawa, H.; Shimada, K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn. Circ. J., 2001, 65, 71-75.
44. Zhou, H.Z.; Ma, X.; Gray, M.O.; Zhu, B.Q.; Nguyen, A.P.; Baker, A.J.; Simonis, U.; Cecchini, G.; Lovett, D.H.; Karliner, J.S. Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem. Biophys. Res. Commun., 2007, 358, 189-195.
45. Yasmin, McEniery, C.M.; Wallace, S.; Dakham, Z.; Pulsalkar, P.; Maki-Petaja, K.; Ashby, M.J.; Cockcroft, J.R.; Wilkinson, I.B. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 372.
46. Delgado-Enciso, I.; Gonzalez-Hernandez, N.A.; Baltazar- Rodriguez, L.M.; Millan-Guerrero, R.O.; Newton-Sanchez, O.; Bayardo-Noriega, A.; Aleman-Mireles, A.; Enriquez-Maldonado, I.G.; Anaya-Carrillo, M.J.; Rojas-Martinez, A.; Ortiz-Lopez, R. Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. J. Genet. 2009, 88, 249-252.
47. Vasku, A.; Goldbergová, M.; Hollá, L.I.; Spinarová, L.; Spinar, J.; Vítovec, J.; Vácha, J. Two MMP-2 promoter polymorphisms (- 790T/G and -735C/T) in chronic heart failure. Clin. Chem. Lab. Med., 2003, 41, 1299-1303.
48. Hlatky, M.A.; Ashley, E.; Quertermous, T.; Boothroyd, D.B.; Ridker, P.; Southwick, A.; Myers, R.M.; Iribarren, C.; Fortmann, S.P.; Go, A.S.; Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am. Heart J., 2007, 154, 1043-1051.
49. Horne, B.D.; Camp, N.J.; Carlquist, J.F.; Muhlestein, J.B.; Kolek, M.J.; Nicholas, Z.P.; Anderson, J.L. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am. Heart J., 2007, 154, 751-758.
50. Kunte, H.; Kunte, G.; Busch, M.A.; Weichert, W.; Ruckert, R.I.; Harms, L. Differences in carotid plaque content of macrophages, T cells and MMP-9 between patients with embolic and hemodynamic cerebral ischemia due to symptomatic carotid stenosis. Atherosclerosis, 2010, 211, 456-460.
51. Loftus, I.M.; Naylor, A.R.; Goodall, S.; Crowther, M.; Jones, L.; Bell, P.R.; Thompson, M.M. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke, 2000, 31, 40-47.
52. Vine, N.; Powell, J.T. Metalloproteinases in degenerative aortic disease. Clin. Sci. (Lond.), 1991, 81, 233-239.
53. Galis, Z.S.; Sukhova, G.K.; Libby, P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB, J., 1995, 9, 974-980.
54. Chen, F.; Eriksson, P.; Hansson, G.K.; Herzfeld, I.; Klein, M.; Hansson, L.O.; Valen, G. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int. J. Mol. Med., 2005, 15, 57-65.
55. Formato, M.; Farina, M.; Spirito, R.; Maggioni, M.; Guarino, A.; Cherchi, G.M.; Biglioli, P.; Edelstein, C.; Scanu, A.M. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 129-135.
56. Luttun, A.; Lutgens, E.; Manderveld, A.; Maris, K.; Collen, D.; Carmeliet, P.; Moons, L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation, 2004, 109, 1408-1414.
57. Johnson, C.; Galis, Z.S. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 54-60.
58. Davies, M.J. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation, 1998, 97, 2382-2383.
59. Park, J.E.; Keller, G.A.; Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell., 1993, 4, 1317-1326.
60. Papalambros, E.; Sigala, F.; Georgopoulos, S.; Panou, N.; Kavatzas, N.; Agapitos, M.; Bastounis, E. Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc. Dis., 2004, 18, 160-165.
61. Davies, M.J.; Richardson, P.D.; Woolf, N.; Katz, D.R.; Mann, J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J., 1993, 69, 377-381.
62. Kalela, A.; Koivu, T.A.; Sisto, T.; Kanervisto, J.; Höyhtyä, M.; Sillanaukee, P.; Lehtimäki, T.; Nikkari, ST. Serum matrix metalloproteinase- 9 concentration in angiographically assessed coronary artery disease. Scand. J. Clin. Lab. Invest., 2002, 62, 337-342.
63. Bittner, A.; Alcaíno, H.; Castro, P.F.; Pérez, O.; Corbalán, R.; Troncoso, R.; Chiong, M.; Mellado, R.; Moraga, F.; Zanolli, D.; Winter, J.L.; Zamorano, J.J.; Díaz-Araya, G.; Lavandero, S. Matrix metalloproteinase-9 activity is associated to oxidative stress in patients with acute coronary syndrome. Int. J. Cardiol.; 2010, 143, 98-100.
64. Blankenberg, S.; Rupprecht, H.J.; Poirier, O.; Bickel, C.; Smieja, M.; Hafner, G.; Meyer, J.; Cambien, F.; Tiret, L; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003, 107, 1579-1585.
65. Brunner, S.; Kim, J.O.; Methe, H. Relation of matrix metalloproteinase- 9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am. J. Cardiol., 2010, 105, 429-434.
66. Higo, S.; Uematsu, M.; Yamagishi, M.; Ishibashi-Ueda, H.; Awata, M.; Morozumi, T.; Ohara, T.; Nanto, S.; Nagata, S. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ. J., 2005, 69, 1180-1185.
67. Kai, H.; Ikeda, H.; Yasukawa, H.; Kai, M.; Seki, Y.; Kuwahara, F.; Ueno, T.; Sugi, K.; Imaizumi, T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol., 1998, 32, 368-372.
68. Kelly, D.; Khan, S.Q.; Thompson, M.; Cockerill, G.; Ng, L.L.; Samani, N.; Squire, I.B. Plasma tissue inhibitor of metalloproteinase- 1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur. Heart J., 2008, 29, 2116-2124.
69. Squire, I.B.; Evans, J.; Ng, L.L.; Loftus, I.M.; Thompson, M.M. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J. Card. Fail., 2004, 10, 328-333.
70. Welsh, P.; Whincup, P.H.; Papacosta, O.; Wannamethee, S.G.; Lennon, L.; Thomson, A.; Rumley, A.; Lowe, G.D. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM, 2008, 101, 785-791.
71. Cho, H.J.; Chae, I.H.; Park, K.W.; Ju, J.R.; Oh, S.; Lee, M.M.; Park, Y.B. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J. Hum. Genet., 2002, 47, 88-91.
72. Zhang, B.; Ye, S.; Herrmann, S.M.; Eriksson, P.; de Maat, M.; Evans, A.; Arveiler, D.; Luc, G.; Cambien, F.; Hamsten, A.; Watkins, H.; Henney, A.M. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 1999, 99, 1788-1794.
73. Wang, J.; Warzecha, D.; Wilcken, D.; Wang, X.L. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin. Sci. (Lond.), 2001, 101, 87-92.
74. Zhou, S.; Feely, J.; Spiers, J.P.; Mahmud, A. Matrix metalloproteinase- 9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J. Hum. Hypertens., 2007, 21, 861-867.
75. Derosa, G.; D'Angelo, A.; Ciccarelli, L.; Piccinni, M.N.; Pricolo, F.; Salvadeo, S.; Montagna, L.; Gravina, A.; Ferrari, I.; Galli, S.; Paniga, S.; Tinelli, C.; Cicero, A.F. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium, 2006, 13, 227-231.
76. Medley, T.L.; Cole, T.J.; Dart, A.M.; Gatzka, C.D.; Kingwell, B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1479-1484.
77. Peters, D.G.; Kassam, A.; St. Jean P.L.; Yonas, H.; Ferrell, R.E. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke, 1999, 30, 2612-2616.
78. Szczudlik, P.; Borratynska, A. Association between the -1562 C/T MMP-9 polymorphism and cerebrovascular disease in a Polish population. Neurol. Neurochir. Pol., 2010, 44, 350-357.
79. Fiotti, N.; Zivadinov, R.; Altamura, N.; Nasuelli, D.; Bratina, A.; Tommasi, M.A.; Bosco, A.; Locatelli, L.; Grop, A.; Cazzato, G.; Guarnieri, G.; Giansante, C.; Zorzon, M. MMP-9 microsatellite polymorphism and multiple sclerosis. J. Neuroimmunol., 2004, 152, 147-153.
80. Fiotti, N.; Altamura, N.; Fisicaro, M.; Carraro, N.; Adovasio, R.; Sarra, V.M.; Uxa, L.; Guarnieri, G.; Baxter, B.T.; Giansante, C. MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis, 2005, 182, 287-292.
81. Wang, Y.; Su, Y.; Xu, Y.; Pan, S.H.; Liu, G.D. Genetic polymorphism c.1562C>T of the MMP-9 is associated with macroangiopathy in type 2 diabetes mellitus. Biochem. Biophys. Res. Commun. 2010, 391, 113-117.
82. Chen, L.; Wang, X.; Carter, S.A.; Shen, Y.H.; Bartsch, H.R.; Thompson, R.W.; Coselli, J.S.; Wilcken, D.L.; Wang, X.L.; Le- Maire, S.A. A single nucleotide polymorphism in the matrix metalloproteinase 9 gene (-8202A/G) is associated with thoracic aortic aneurysms and thoracic aortic dissection. J. Thorac. Cardiovasc, Surg., 2006, 131, 1045-1052.
83. Ye, S.; Gale, C.R.; Martyn, C.N. Variation in the matrix metalloproteinase- 1 gene and risk of coronary heart disease. Eur. Heart J., 2003, 24, 1668-71.
84. Nojiri, T.; Morita, H.; Imai, Y.; Maemura, K.; Ohno, M.; Ogasawara, K.; Aizawa, T.; Saito, A.; Hayashi, D.; Hirata, Y.; Sugiyama, T.; Yamazaki, T.; Nagai, R. Genetic variations of matrix metalloproteinase- 1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int. J. Cardiol., 2003, 92, 181-186.
85. Lamblin, N.; Bauters, C.; Hermant, X.; Lablanche, J.M.; Helbecque, N.; Amouyel, P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J. Am. Coll. Cardiol., 2002, 40, 43-48.
86. Vasku, A.; Goldbergová, M.; Izakovicová, Hollá. L.; Sisková, L.; Groch, L.; Beránek, M.; Tschöplová, S.; Znojil, V.; Vácha, J. A haplotype constituted of four MMP-2 promoter polymorphisms (- 1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol., 2004, 22, 585-591.
87. Jormsjo, S.; Whatling, C.; Walter, D.H.; Zeiher, A.M.; Hamsten, A.; Eriksson, P. Allele-specific regulation of matrix metalloproteinase- 7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1834-1839.
88. Terashima, M.; Akita, H.; Kanazawa, K.; Inoue, N.; Yamada, S.; Ito, K.; Matsuda, Y.; Takai, E.; Iwai, C.; Kurogane, H.; Yoshida, Y.; Yokoyama, M. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation, 1999, 99, 2717-2119.
89. Schwarz, A.; Haberbosch, W.; Tillmanns, H.; Gardemann, A. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis. Markers, 2002, 18, 121-128.
90. Yamada, Y.; Izawa, H.; Ichihara, S.; Takatsu, F.; Ishihara, H.; Hirayama, H.; Sone, T.; Tanaka, M.; Yokota, M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N. Engl. J. Med., 2002, 347, 1916-1923.
91. Tobin, M.D.; Braund, P.S.; Burton, P.R.; Thompson, J.R.; Steeds, R.; Channer, K.; Cheng, S.; Lindpaintner, K.; Samani, N.J. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur. Heart J., 2004, 25, 459-467.
92. Shioji, K.; Kokubo, Y.; Goto, Y.; Nonogi, H.; Iwai, N. An association analysis between genetic polymorphisms of matrix metalloproteinase- 3 and methylenetetrahydrofolate reductase and myocardial infarction in Japanese. J. Thromb. Haemost., 2004, 2, 527-528.
93. Zhou, X.; Huang, J.; Chen, J.; Su, S.; Chen, R.; Gu, D. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb. Haemost., 2004, 92, 867-873.
94. Samnegård, A.; Silveira, A.; Lundman, P.; Boquist, S.; Odeberg, J.; Hulthe, J.; McPheat, W.; Tornvall, P.; Bergstrand, L.; Ericsson, C.G.; Hamsten, A.; Eriksson, P. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction. J. Intern. Med., 2005, 258, 411-419.
95. Morgan, T.M.; Krumholz, H.M.; Lifton, R.P.; J.A.; Spertus, J.A. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA, 2007, 297, 1551-1561.
96. Koch, W.; de Waha, A.; Hoppmann, P.; Schömig, A.; Kastrati, A. Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase- 3 gene in coronary disease: case-control study and a metaanalysis. Atherosclerosis, 2010, 208, 171e6.
97. Ghaderian, S.M.; Akbarzadeh, Najar R.; Tabatabaei, Panah, A.S. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron. Artery Dis., 2010, 21, 330-335.
98. Pearce, E.; Tregouet, D.A.; Samnegård, A.; Morgan, A.R.; Cox, C.; Hamsten, A.; Eriksson, P.; Ye, S. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ. Res., 2005, 97, 1070-1076.
99. Román-García, P.; Coto, E.; Reguero, J.R.; Cannata-Andía, J.B.; Lozano, I.; Avanzas, P.; Morís, C.; Rodríguez, I. Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a caseecontrol study in a Spanish population. Coron. Artery Dis., 2009, 20, 383-386.
100. Delgado-Enciso, I.; Gonzalez-Hernandez, N.A.; Baltazar- Rodriguez, L.M.; Millan-Guerrero RO, Newton-Sanchez O, Bayardo- Noriega A, Aleman-Mireles A, Enriquez-Maldonado, I.G.; Anaya-Carrillo, M.J.; Rojas-Martinez, A.; Ortiz-Lopez, R. Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. J. Genet., 2009, 88, 249-252.
101. Alp, E.; Menevse, S.; Tulmac, M.; Yilmaz, A.; Yalcin, R.; Cengel, A. The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet. Test Mol. Biomarkers, 2010. 15, 193-202.